Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study
Open Access
- 11 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3), e58827
- https://doi.org/10.1371/journal.pone.0058827
Abstract
In Taiwan, new H1N1 monovalent vaccines without adjuvant and with MF59® adjuvant were used in the nationwide vaccination campaign beginning on November 1, 2009. From November 2009 through February 2010, the authors identified recipients of H1N1 vaccines who were diagnosed with adverse events of special interest (AESIs) in a large-linked safety database, and used the self-controlled case series (SCCS) method to examine the risk of each AESI in the 0–42 days after H1N1 vaccination. Of the 3.5 million doses of H1N1 vaccines administered and captured in the linked database, the SCCS analysis of Guillain-Barré syndrome (GBS) found an incidence rate ratio of 3.81 (95% confidence interval 0.43–33.85) within 0–42 days after nonadjuvanted H1N1 vaccination and no cases after MF59®-adjuvanted H1N1 vaccination. The risks of other AESIs were, in general, not increased in any of the predefined postvaccination risk periods and age groups. The databases and infrastructure created for H1N1 vaccine safety evaluation may serve as a model for safety, effectiveness and coverage studies of licensed vaccines in Taiwan.This publication has 35 references indexed in Scilit:
- Nationwide Surveillance of Influenza during the Pandemic (2009–10) and Post-Pandemic (2010–11) Periods in TaiwanPLOS ONE, 2012
- Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011Vaccine, 2012
- H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink ProjectAmerican Journal of Preventive Medicine, 2011
- Guillain-Barre Syndrome, Influenzalike Illnesses, and Influenza Vaccination During Seasons With and Without Circulating A/H1N1 VirusesAmerican Journal of Epidemiology, 2011
- Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccinesThe Lancet, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineThe New England Journal of Medicine, 2009
- Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety Datalink ProjectAmerican Journal of Epidemiology, 2009
- Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control studyThe Lancet, 2008
- Tutorial in biostatistics: the self‐controlled case series methodStatistics in Medicine, 2005
- Risk of Myocardial Infarction and Stroke after Acute Infection or VaccinationThe New England Journal of Medicine, 2004